Two Sigma Advisers’s Quest Diagnostics DGX Stock Holding History

Two Sigma Advisers’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-9,000	Closed	-$521K	–	2487
2014 Q1	$521K	Buy	+9,000	New	+$482K	﹤0.01%	1540

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Two Sigma Advisers's DGX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 1,700 shares — an estimated $295K sold.

Two Sigma Advisers first reported a position in DGX in Q3 2013 and held it in 34 quarters. The position peaked at $103M in Q1 2019. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Two Sigma Advisers reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 1,700 Quest Diagnostics shares in Q1 2026, an estimated $295K.
Two Sigma Advisers first reported a position in Quest Diagnostics in Q3 2013 and held it in 34 quarters.
Two Sigma Advisers's Quest Diagnostics position peaked at $103M in Q1 2019.
1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.